PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Jul 13, 2020

byprotokinetixp

Exploring a cure for diabetes

According to the Centers for Disease Control and Prevention (CDC), there were more than 30.3 million diagnosed cases of diabetes in the U.S. in 2015, and more than 100 million...Read more

Jul 13, 2020

bybhenderson

Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada

Marietta, Ohio, July 13, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of March 24, 2020. The amendments...Read more

Jul 07, 2020

bybhenderson

dry-eye

ProtoKinetix AAGP® Dry Eye Program Advancing

Marietta, Ohio, July 7, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye...Read more

Apr 06, 2020

bybhenderson

dry-eye

ProtoKinetix AAGP® Exhibits Efficacy and Safety in Model of Dry Eye Disease

Marietta, Ohio, April 6, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, having recently announced filing for patent protection for new applications of...Read more

Mar 24, 2020

bybhenderson

ProtoKinetix Ready to Ship AAGP® to the University of Alberta for the Continuation of Phase 1 Human Trials

Marietta, Ohio, March 24, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of January 24, 2020....Read more

Mar 19, 2020

bybhenderson

dry-eye

ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

Marietta, Ohio, March 19, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecule. During recent testing conducted by...Read more

Feb 19, 2020

bybhenderson

ProtoKinetix Announces Progress in the use of AAGP® in Cardiovascular Medicine

Marietta, Ohio, Feb. 19, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders. “Using isolated cardiac cells, we demonstrated that...Read more

Feb 11, 2020

bybhenderson

ProtoKinetix files for Patent protection for the use of AAGP® in transplant medicine

Marietta, Ohio, February 11, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for a new application of its AAGP® molecule. During recent...Read more

Jan 24, 2020

byncaipen

Transplants

ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that the Company has taken procession of an additional 200 grams of GMP grade PKX-001 (AAGP®) molecule. We are...Read more

Jan 06, 2020

byncaipen

Ophthalmology

ProtoKinetix AAGP® Dry Eye Therapy Testing Results

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.